Sully, K <br/><br/>
The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling.  [electronic resource] 

 -  Oncogene  Jul 2013 
 - 3254-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2012.338  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Agammaglobulinaemia Tyrosine Kinase<br/>Animals<br/>Blotting, Western<br/>Cell Line<br/>Cell Transformation, Neoplastic--drug effects<br/>Epidermis--drug effects<br/>Humans<br/>Immunohistochemistry<br/>Immunoprecipitation<br/>Immunosuppressive Agents--pharmacology<br/>Isoenzymes--metabolism<br/>Keratinocytes--drug effects<br/>Mice<br/>Phosphorylation<br/>Protein-Tyrosine Kinases--metabolism<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Signal Transduction--drug effects<br/>Sirolimus--pharmacology<br/>Skin<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Ultraviolet Rays